New research suggests that zinc does far more than support immunity, revealing intricate molecular switches that may influence how the heart responds to inflammatory injury.
Review: Zinc: A metallic shield against cardiac inflammation. Image Credit: Cagkan Sayin / Shutterstock
In a recent review published in the journal Metallomics, researchers synthesized a broad body of mechanistic and clinical literature investigating the role of Zinc (Zn) in modulating cardiac inflammation. The review collated literature on Zn’s biochemical, therapeutic, and immunological effects. It concluded that Zn deficiency is a potentially significant yet modifiable risk factor for cardiac inflammatory diseases (CIDs), such as myocarditis and pericarditis, based largely on mechanistic, observational, and preclinical evidence rather than definitive randomized clinical trials.
Zn was found to act primarily as an antioxidant cofactor and signaling molecule, with evidence suggesting it may help modulate inflammatory cytokine signaling and oxidative stress pathways implicated in heart tissue damage. The review posits that Zn supplementation represents a promising, accessible strategy to bolster future cardiovascular resilience, while emphasizing that much of the supporting evidence remains preclinical or mechanistic in nature and that randomized controlled trials in patients with myocarditis or pericarditis are currently limited.
Biological Importance of Zinc and Cardiac Inflammation Context
Zinc (Zn) is an essential trace element found in the human body at trace levels. Despite its limited physiological amount (~2 g), the metal is now known to be indispensable for immune regulation, wound healing, and DNA synthesis.
Recent years have witnessed continued clinical and research attention toward inflammatory heart conditions, particularly myocarditis and pericarditis. These conditions have been associated in some cases with sudden cardiac death in young adults and athletes and have frequently been observed to be triggered by viral infections (including SARS-CoV-2) or autoimmune responses.
Mechanistic investigations suggest that these outcomes are driven by autoimmune responses, which result in the release of substantial concentrations of pro-inflammatory cytokines that injure the very tissue they were meant to protect.
Current interventions against inflammatory heart conditions often focus on symptom management or broad immunosuppression. Unfortunately, these treatments rarely address the underlying nutritional and biochemical deficits that may contribute to dysregulated inflammatory responses, although cardiac inflammation is multifactorial and not attributable solely to zinc status.
Scope and Focus of the Review
This review synthesizes recent preclinical and clinical literature on Zn deficiency and its association with adverse inflammatory heart conditions to determine whether Zn supplementation may serve as an accessible, safe intervention against these potentially lethal cardiovascular conditions.
The review primarily focused on elucidating the "Redox Zinc Switch", a relatively recently discovered biological mechanism in which Zinc is released from proteins during stress, acting as a signal that subsequently modulates key inflammatory pathways (e.g., Nuclear Factor kappa B [NF-κB]).
Furthermore, the review summarized mechanistic, in vitro, and animal-model evidence linking Zn homeostasis to ischemia (blood flow restriction) and reperfusion (restoration of blood flow) injury, noting that direct assessment of cardiac Zn loss in humans remains technically challenging and that circulating plasma zinc concentrations may not reliably reflect intracellular cardiac zinc status.
Finally, the review evaluated Zn’s present and future therapeutic potential by focusing on Zn ionophores (molecules that facilitate Zn transport into cells) and examining the impact of Zn on viral replication, particularly in studies conducted during the COVID-19 era.
Mechanistic Pathways: Anti-Inflammatory and Antioxidant Roles
The review attributed Zn’s protective function to three mechanistically distinct yet physiologically interconnected biological functions.
First, Zn was found to act as a molecular "brake" on inflammation by inhibiting NF-κB, a protein complex previously shown to control DNA transcription and cell survival. The review found that under ‘normal’ physiological conditions, NF-κB is inactive. However, during an infection, it triggers the release of inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).
Specifically, Zn was shown to induce and promote A20 expression. A20 is a proteinaceous negative regulator that was found to effectively halt the NF-κB signaling pathway. For example, in studies using HL-60 cell lines, Zn supplementation significantly enhanced A20 activity, thereby dampening the inflammatory response.
Second, Zn demonstrated potent antioxidant activity, making it an ideal therapeutic intervention for the heart, given its high susceptibility to oxidative stress from Reactive Oxygen Species (ROS). Zinc is a known essential cofactor for the enzyme superoxide dismutase (Cu/Zn-SOD), which has been found to be an effective neutralizing species in the inactivation of toxic superoxide radicals.
Furthermore, the review cites a growing body of data showing that Zn both inhibits NADPH oxidase, an enzyme implicated in ROS generation, and boosts glutathione synthesis, a potent antioxidant.
The Redox Zinc Switch and Cellular Signaling
Finally, the review highlights preclinical research (animal models of cardiac ischemia), which found that oxidative stress causes proteins to release their bound Zn, a process now termed the "Redox Zinc Switch".
Released Zinc was observed to function as a secondary messenger, activating protective signaling pathways like PKC and MAPK to preserve heart tissue. However, this safety mechanism was found to fail under Zinc-deficient conditions, wherein these signaling proteins degrade, leading to cell death and cardiac remodeling.
Conclusions and Translational Considerations
The present review posits that maintaining optimal Zinc levels (through diet or supplementation) may offer prophylactic or adjunctive therapeutic benefit for myocarditis and pericarditis. It, however, highlights that current blood-based Zn biomarkers lack sensitivity, often failing to detect marginal cellular deficiencies.
The authors suggest that future clinical strategies may need to utilize Zn ionophores, such as quercetin, to ensure the mineral penetrates the cardiac tissue where it is needed most. It concludes that medical practice may need to reconsider Zn not merely as a general immune-support supplement but as a potentially targeted adjunct in strategies aimed at augmenting cardiovascular resilience, pending further translational and clinical validation, while recognizing that both zinc deficiency and excessive supplementation can disrupt physiological homeostasis and require careful clinical consideration.
Acute heart failure linked to high readmission and death rates